Welcome to our dedicated page for CLVS news (Ticker: CLVS), a resource for investors and traders seeking the latest updates and insights on CLVS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CLVS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CLVS's position in the market.
Clovis Oncology (NASDAQ:CLVS) reported Q1 2021 financial results, indicating global net product revenues for Rubraca of $38.1 million, an 11% year-over-year decline due to COVID-19-related impacts on patient diagnoses. Research and development expenses decreased 23% to $52.8 million, while selling, general, and administrative expenses fell 30% to $29.9 million. The net loss narrowed to $66.3 million, or $0.64 per share, improving from a loss of $99.3 million in Q1 2020. The company anticipates critical data from the ATHENA study in the second half of 2021, and plans to start the Phase 1 LuMIERE study for FAP-2286 this quarter.
Clovis Oncology, Inc. (Nasdaq: CLVS) announced that President and CEO Patrick J. Mahaffy will present at the Bank of America 2021 Health Care Conference on May 11, 2021, at 5:00 p.m. Eastern time. The presentation will be virtual, with a live webcast accessible via the company’s investor relations website. A replay of the webcast will be available for 30 days post-event. Clovis Oncology focuses on developing and commercializing innovative anti-cancer agents and targeting specific cancer populations with accompanying diagnostic tools.
Clovis Oncology, Inc. (NASDAQ: CLVS) is set to release its first quarter 2021 financial results on May 5, 2021, prior to the US market opening. A conference call with senior management will be held at 8:30 a.m. ET to discuss the results in detail. Participants can join the call via dial-in numbers provided, with a dedicated international line available. The live event will also be streamed on Clovis' website, and a replay will be accessible for 30 days. The company focuses on innovative anti-cancer treatments in various global markets.
Clovis Oncology, Inc. (NASDAQ: CLVS) revealed Phase 1 data on Rubraca at the AACR Virtual Annual Meeting, scheduled from April 10-15, 2021. The findings included the combination of Rubraca and Xtandi for advanced prostate cancer and Rubraca monotherapy in Japanese patients. Results showed unselected metastatic castration-resistant prostate cancer patients experienced PSA declines, and Rubraca was safe for Japanese patients, achieving an 18.5% objective response rate. These results support further studies, including the upcoming CASPAR Phase 3 trial for mCRPC patients.
Clovis Oncology (NASDAQ: CLVS) presented data from the Phase 3 ARIEL4 study of Rubraca (rucaparib) at the SGO Virtual Annual Meeting. The study shows Rubraca significantly improves progression-free survival (PFS) compared to standard chemotherapy in patients with advanced, relapsed ovarian cancer and a BRCA mutation after two or more lines of chemotherapy. In the primary efficacy population (n=325), median PFS was 7.4 months for Rubraca versus 5.7 months for chemotherapy. The data support Rubraca's role in treating BRCA mutation-positive patients.
Clovis Oncology (NASDAQ:CLVS) reported fourth quarter and full-year 2020 financial results, showing growth in Rubraca revenues, with Q4 net product revenues reaching $43.3 million, a 10% increase from Q4 2019. Total revenues for 2020 were $164.5 million, up 15% year-over-year. R&D expenses decreased by 22% in Q4 and 9% for the year. The company reported a net loss of $99.0 million for Q4 2020 and $369.2 million for the year. Clovis will initiate clinical studies for FAP-2286 in 2021, aiming to improve its pipeline and financial outlook.
Clovis Oncology (NASDAQ: CLVS) will release its fourth quarter and year-end 2020 financial results on February 23, 2021, before U.S. market opening. Management will hold a conference call at 8:30 a.m. ET to elaborate on these results. The call will be available via webcast, and a replay will be accessible for 30 days. Clovis is dedicated to developing and commercializing innovative anti-cancer agents and diagnostic tools aimed at specific cancer subpopulation. For further information, visit www.clovisoncology.com.
Clovis Oncology (NASDAQ: CLVS) announced the presentation of Rubraca data at the ASCO Genitourinary Cancers Virtual Symposium 2021. Key highlights include findings from the Phase 1b RAMP study, which evaluates Rubraca in combination with Xtandi for mCRPC, demonstrating safety and tolerability. The pivotal TRITON2 study data suggest Rubraca's efficacy in BRCA-mutated mCRPC. A new Phase 3 CASPAR trial is set to enroll 1,000 patients, focusing on this combination therapy. The findings aim to guide treatment decisions in prostate cancer management.
Clovis Oncology, Inc. (CLVS) announced the acceptance of two abstracts for poster presentations at the ASCO 2021 Genitourinary Cancers Symposium, focusing on Rubraca® (rucaparib) in metastatic castration-resistant prostate cancer (mCRPC). The data aims to deepen understanding of Rubraca's clinical role and its potential as a treatment option. Presentations will occur virtually from February 11-13, 2021, with extensive insights into gene alterations and safety data. Rubraca is currently FDA-approved for mCRPC patients with BRCA mutations. Details on safety, potential MDS/AML risks, and adverse reactions are also highlighted.
Clovis Oncology (NASDAQ:CLVS) reported preliminary global product revenues for Q4 and FY 2020, estimating $43.0M - $43.5M in Q4 revenue, up from $38.8M in Q3 2020, and $39.3M in Q4 2019. Full-year revenues reached $164.2M - $164.7M, up from $143.0M in 2019. The company had $240M in cash and equivalents, expected to support operations into early 2023. Upcoming events include a presentation at the J.P. Morgan Healthcare Conference and the release of detailed Q4 and FY results on February 23, 2021.
FAQ
What is the market cap of CLVS (CLVS)?
